Dec 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's (MRK.N), opens new tab cholesterol pill and its cancer therapy, making them ...
Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...
The FDA has released the second batch of recipients for the new "national priority voucher" program, with executives for two of the beneficiaries appearing in the Oval Office with President Donald ...
The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, with the exception of Eli Lilly’s orforglipron, the vouchers are for drugs ...
This article originally appeared on PolitiFact. As images of the White House's demolished East Wing led the national news, top Democrats shared a video of White House Press Secretary Karoline Leavitt ...
Prominent Democrats have shared a viral clip they say shows White House press secretary Karoline Leavitt describing the new White House ballroom as President Donald Trump's "main priority," but that ...
Top Democrats in the Senate and House of Representatives have taken a Thursday quote from the White House press secretary out of context to deliver a misleading attack on President Donald Trump. A ...
Katie Nadworny is an Istanbul-based writer who specializes in stories at the intersection of culture and politics in Turkey, Eastern Europe, and the Middle East. She has lived in Turkey for nearly a ...
When I first hopped on the new Priority Skyline Smart‑Shift e-bike, I wasn’t exactly sure what to expect. I’ve ridden dozens and dozens of commuter e-bikes, some fancier than others, but it’s rare to ...
Aug 11 (Reuters) - British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority review of gepotidacin, an oral antibiotic to treat sexually ...
The FDA has begun accepting applications for a priority pathway designed to slash review times to between one and two months, giving developers of medicines that align with U.S. national health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback